Background: Pulmonary exacerbations (P Exs) are important in cystic fibrosis (CF). They are very common, and are associated with poor quality of life. P Exs are regarded as an important end point in clinical trials. Risk factors associated with increase in P Exs have not been examined at a large scale. This study investigates factors associated with P Exs in a large cohort of adolescent and adult patients.
Patients and methods: This is a cross-sectional study on data collected in the South and West Regions in England in 2002. Patients aged 16 years and over were included. Data on age, gender, FEV1, body mass index (BMI), infection with Pseudomonas aeruginosa (Pa) and on CF-related diabetes were included in the analysis. P Ex was defined as an episode treated with IV antibiotics. Forward stepwise multiple regression analysis was performed with the number of P Exs being the independent variable. The rest of the variables were considered to be the dependent variables.
Results: Data from 341 patients (194 female), mean age (SD), 24.9 (8.9) years were available. In 2002, a total of 599 P Exs were reported, median 1.00 range 0—16 P Exs. Using stepwise multiple regression analysis factors associated with increased number of P Exs were: infection with Pa (t-value —5.0, P < 0.0001), FEV1, (t-value —4.9, P < 0.0001) and diabetes mellitus, (t-value —2.1, P = 0.04). Age, gender and BMI did not influence the annual number of exacerbations.
Conclusions: In this study, risk factors for P Exs were found to be as follows: growth of Pa in the sputum, reduced FEV1 and CF-related diabetes mellitus. Chronic Respiratory Disease 2008; 5: 29—33
Ramsay BWManagement of pulmonary disease in patients with cystic fibrosis . NEJM1996; 335: 179—88.
2.
Marshall BCPulmonary exacerbation in cystic fibrosis . It's time to be explicit. AJRCCM2004; 169: 781—2.
3.
Liu TG , Adler FR , Fitzsimmons SC , Cahill BC , Hibbs JR , Marshall BCPredictive 5 years survivorship model of cystic fibrosis . Am J Epidem2001; 153: 345—52.
4.
Britto MT , Kotagal UR , Hornung RW , Atherton HD , Tsevat J. , Wilmott RWImpact of recent exacerbations on quality of life on patients with cystic fibrosis . Chest2002; 121: 64—72.
5.
Jarad NA , Jeffcote T. , Higgs, S. , Giles K.Factors influencing reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area . Chronic Respir J2005; 2: 133—7.
6.
Ramsay BW , Boat TFOutcome measures for clinical trials in CF: summary of cystic fibrosis conference . J Pediatrics1994; 124: 177—92.
7.
Konstan MW , Byard PT , Hoppel CL , Davies PBEffect of high-dose ibuprofen in patients with CF . NEJM1995; 332: 848—54.
8.
Ramsay BW , Pepe MS , Quan JM , Otto KL , Montgomery AB , Williams-Warren J. et al. Efficacy and safety of chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis . NEJM1999; 340: 23—30.
9.
Fuchs HJ , Borowitz DS , Christiansin DH , Morris EM , Nash ML , Ramsay BWEffect of aerolised recombinant human DNase on exacerbation of respiratory symptoms and on pulmonary function in patients with cystic fibrosis . NEJM1994; 331: 637—42.
10.
Dakin C. , Henry RL , Field P. , Morton J.Defining an exacerbation of pulmonary disease in Cystic Fibrosis . Paediatr Pulmonol2001; 31: 436—42.
11.
Rosenfeld M. , Emerson J. , Williams-Warren J. et al. Defining pulmonary exacerbation in cystic fibrosis . J Paediatric2001; 139: 359—65.
12.
Kanga J. , Kuhn , Craigmyle Lois , Harverstock D. , Churcu D.Cystic fibrosis clinical score: A new scoring system to evaluate pulmonary exacerbations . Clinical Therapeutics1999; 21: 1343—56.
13.
Higgs S. , Jarad NANational United Kingdom Survey of cystic fibrosis pulmonary exacerbations: Management variation amongst paediatric and adult physicians . Thorax2005; 60: 94 .
14.
Block JK , Vandemheen KL , Tullis E. et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria . Thorax2006; 61: 969—74.
15.
Liou TA , Ray GT , Farmer G. , Shay GFThe cost of medical care for patients with cystic fibrosis in a health maintenance organisation . Paediatrics1999; 103: 72—8.
16.
Pauwels RA , Lofdahl CG , Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease . NEJM1999; 340: 1948—53.
17.
Burge PS , Calverley PM , Jones PW , Spencer S. , Anderson JA , Maslen TKRandomised double blind placebo controlled study on fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial . BMJ2000; 320: 1297—303.
18.
De Jaeger J. , Burt J. , Jarad NANumber of exacerbations and days of IV antibiotics are associated with accelerated decline in lung function in a cohort of adult CF patients . J Cyst Fibrosis2004; 3: S215 .
19.
Kerem E. , Carey M. , Gold R. et al. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with pseudomonas aeruginosa . J Paediatrics1990; 116: 714—19.
20.
Kosorok MR , Zeng L. , West SEH et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition . Paediatr Pulmonol2001; 32: 277—87.
21.
Emerson J. , Rosenfeld M. , McNamara S. , Ramsay B. , Gibson RLPseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis . Paediatr Pulmonol2002; 34: 91—100.
22.
Burns JL , Gibson RL , McNamara S. et al. Longitudinal assessment of pseudomonas aeruginosa in young children in cystic fibrosis . J Infect Dis2001; 183: 444—52.
23.
Zhanhai L. , Kosorok MR , Farrell PM et al. Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis . JAMA2005; 293: 581—8.
24.
Rosenecker J. , Hofler R. , Steinkamp G. et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome . Eur J Resp Med2001; 6: 345—50.
25.
Koch C. , Rainisio M. , Madessani U. et al. Presence of cystic fibrosisrelated diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis. Data from the European Epidemiologic Registry of Cystic Fibrosis . Pediatr Pulmonol2001; 32: 343—50.
26.
Rolon MA , Benali K. , Munck A. et al. Cystic fibrosis-related diabetes mellitus: clinical impact of pre-diabetes and effects of insulin therapy . Acta Paediatrica2001; 90: 860—7.
27.
Lanng S. , Thorsteinsson B. , Nerup J. , Koch C.Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis . Eur J Paediatrics1992 ; 151: 684—7.
28.
Giles K. , Connett G. , Ilangovan P. , Cade A. , Prendiville A.The impact of a future diagnosis of cystic fibrosis-related diabetes mellitus (CFRD) on disease severity in patients with cystic fibrosis (CF) in the South West of England . J Cyst Fibrosis2004; 3(Suppl 1): S86 .
29.
Sharma R. , Florea VG , Bolger AP et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis . Thorax2001; 56: 746—50.
30.
Koch C. , Rainisio M. , Madessani U. et al. Presence of cystic fibrosisrelated diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis . Data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatric Pulmonol2001; 32: 343—50.
31.
Rabin HR , Butler SM , Wohl ME et al. Pulmonary exacerbations in cystic fibrosis . Paediatr Pulmonol2004; 37: 400—6.
32.
Goss CH , Burns JLExacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis . Thorax2007; 62: 360—67.
